Amylyx Pharmaceuticals vs Prothena Corp Public
AMLX and PRTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and PRTA compare
Amylyx Pharmaceuticals is the larger company, worth 7.9 times as much as Prothena Corp Public ($3.3B against $423M).
Prothena Corp Public scores higher on the StockData Score (12 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | PRTA |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $423M |
| Share price | $29.86 | $8.23 |
| Change, 1 year | 135% | −21.5% |
| Change, 5 years | 178% | −86.0% |
| Beta (5Y) | 1.15 | 0.86 |
| Employees | 136 | 67 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 8.0× |
| P/B | 4.4× | 1.6× (better) |
| Fair value | – | $9.99 |
| Margin of safety | – | 17.6% |
| Growth | ||
| Revenue growth (TTM) | – | 347% |
| Revenue growth, 5Y average | – | 62.6% |
| Profitability | ||
| Operating margin | – | −64.6% |
| Net margin | – | −45.4% |
| Return on equity | −30.1% | −8.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.81 (better) | 23.95 |
| Altman Z-score | 59.22 (better) | 11.50 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 92.2% |
| Held by insiders | 8.0% | 32.0% |
| Insider net buying, 12 months | −$10.0M | $13.1M (better) |
| Short interest, % of float | 12.5% | 22.7% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- PRTA stock overview
- PRTA income statement
- PRTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.